Bleselumab clinical trials
Also written ASKP1240.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses bleselumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Astellas Pharma Global Development, Inc. (4) · Astellas Pharma Inc (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bleselumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01780844Written as ASKP1240
- A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney TransplantationCompletedPhase 1Astellas Pharma IncNCT01279538Written as bleselumab
- A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01585233Written as ASKP1240
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02921789Written as Bleselumab
- Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240CompletedPhase 1Astellas Pharma Global Development, Inc.NCT01582399Written as ASKP1240
Codes
What other systems call bleselumab · ClinicalTrials.gg INT006421
- MeSH (NLM) C586087bleselumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AS3AZ5R46KBLESELUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q48850555bleselumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171700BleselumabOne source FDA
- DrugBank DB15253One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586087 | bleselumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AS3AZ5R46K | BLESELUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48850555 | bleselumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171700 | Bleselumab | One source FDA |
| DrugBank | DB15253 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.